Press Release
September 19, 2022

SparingVision Raises €75 Million In Series B

The Paris Life Sciences team advised a syndicate of investors on the €75M Series B Financing of SparingVision, a genomic medicines company with a mission to translate pioneering science into vision saving treatments.

The round was was co-led by Jeito Capital and UPMC Enterprises Enterprises (University of Pittsburgh Medical Center), with participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness and Ysios Capital.

Proceeds from the financing will be used to fund the first-in-human trials of the Company’s two lead gene-independent assets.

The Goodwin team was led by Anne-Charlotte Rivière and included Johann Gandilhon on corporate aspects.